Regeneron Drug Plus Novo's Semaglutide Cuts Muscle Loss in New Data
REGN sits 40% above its 52-week low of $541.
Summary
New data shows a Regeneron drug combined with Novo Nordisk's semaglutide reduces muscle loss, a key concern in obesity treatment. This is the first report of this specific combination and could strengthen Regeneron's position in the metabolic space. The news follows Regeneron's recent expansion of its Sanofi collaboration and strong Q2 results. No specific upcoming event is named, but the data may influence ongoing development plans.
At the time of this announcement, REGN was trading at $759.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $78.1B. The 52-week trading range was $541.00 to $859.34. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Seeking Alpha.